Development of artificial lung surfactant

人工肺表面活性剂的研制

基本信息

批准号：
05671254
负责人：
KOBAYASHI Tsutomu
金额：
$ 1.28万
依托单位：
Kanazawa University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1993
资助国家：
日本
起止时间：
1993 至 1994
项目状态：
已结题

项目摘要

1. Development of artificial surfactantA) Investigation for the best composition of lipids (1993) : Activity of several reconstituted surfactants that consisted of synthetic dipalmitoylphosphatidylcholine (DPPC) , phosphatidylglycerol (PG) and dioleoylphosphatidylcholine (DOPC) with different ratios plus surfactant-associated proteins-B and-C (SP-B and SP-C) was evaluated in immature rabbits. The surfactant composed of DPPC : PG : DOPC at a ratio of 60 : 20 : 20 showed the best activity.B) Investigation for the best composition of proteins (1994) : Activity of several reconstituted surfactants that consisted of isolated lipids from lung plus different doses of SP-B and SP-C were evaluated in immature rabbits. The surfactant containing SP-B at 0.7% and SP-C at 1.4% improved the static pressure-volume relationship of the lung at the best, but the tidal volume was not completely normalized. Further studies are necessary for method to combine lipids and proteins.2. Treatment of adult repiratory distress syndrome (ARDS) with surfactantA) Intratracheal instillation method (1993) . Instillation of surfactant suspension (50 mg/ml, 2 ml/kg) into the trachea of rats with ARDS that induced by endotoxin (50 mg/kg) improved the arterial oxygen pressure (PaO_2) from 85 mmHg to 345 mmHg (P<0.05) , but caused hypotension.B) Administration of surfactant by inhalation (1994) : Inhalation of surfactant aerosol improved the PaO_2 of ARDS rats from 84 mmHg to 243 mmHg (P<0.05) without causing hypotension.Comments and conclusionsThe present results suggest that inhalation of aerosolized surfactant can apply for treatment of clinical ARDS.We should make haste to develope an effective artificial surfactant.

1. Development of artificial surfactantA) Investigation for the best composition of lipids (1993) : Activity of several reconstituted surfactants that consisted of synthetic dipalmitoylphosphatidylcholine (DPPC) , phosphatidylglycerol (PG) and dioleoylphosphatidylcholine (DOPC) with different ratios plus surfactant-associated proteins-B and-C在未成熟的兔子中评估（SP-B和SP-C）。由DPPC：PG：DOPC组成的表面活性剂的比例为60：20：20，表现出最佳活性。B）研究蛋白质最佳组成的研究（1994年）：几种重构表面活性剂的活性，这些表面活性剂的活性由来自肺部的SP-B和SP-C的分离脂质组成的几种重构表面活性剂的活性在不成熟的兔子中评估了不同剂量的SP-B和SP-C。含有SP-B的表面活性剂在0.7％和1.4％的SP-C中提高了最佳肺的静态压力量 - 但潮汐体积尚未完全归一化。进一步的研究是结合脂质和蛋白质的方法。2。通过表面上的成人抑制遇险综合征（ARDS）处理气管内灌输方法（1993）。将表面活性剂悬浮液（50 mg/ml，2 mL/kg）滴入大鼠的气管中，由内毒素（50 mg/kg）诱导的ARDS（50 mg/kg）改善了动脉氧气压力（PAO_2），从85 mmHg到345 mmHg（p <0.05），但通过高位施加了（p <0.05）对表面活性剂气溶胶的吸入将ARDS大鼠的PAO_2从84 mmHg提高到243 mmHg（p <0.05），而不会引起hypotension.com.com.ment.com和结论，目前的结果表明，吸入雾化的表面活性剂可以使我们的临床疗法适用于我们的临床疗法。